A Phase 2 interventional study of HTX-011 and ZYNRELEF kit components for administration in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Heron Therapeutics · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 320th largest by enrollment, is one of 35 that started in 2019, is one of 43 in phase 2, and was the 182nd registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 35 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
Heron Therapeutics is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 12 (86%) have results posted.
20 studies in Pain, Postoperative by Heron Therapeutics: none open now, 1 under way, none of them phase 3. Of 18 finished, 16 (89%) have results posted.
Among the 20 studies in Pain, Postoperative by Heron Therapeutics, this one is the 19th largest by enrollment, is one of 3 that started in 2019, is one of 10 in phase 2, and was the 13th registered.
Heron Therapeutics’s Pain, Postoperative studies by the year they started, since 2015.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
Among Heron Therapeutics’s 20 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
The main goal of the study was to measure the amount of the active ingredients and other components of HTX-011 in plasma and expressed breast milk over time following postpartum administration in women undergoing a planned C-section. The study also looked at the safety of HTX-011 in these women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HTX-011 (bupivacaine/meloxicam) 300 mg/9 mg via instillation
Drug: HTX-011 · Device: ZYNRELEF kit components for administration
HTX-011 (bupivacaine/meloxicam) 400 mg/12 mg via instillation + oral (PO) non-opioid multimodal analgesic (MMA) regimen
Drug: HTX-011 · Device: ZYNRELEF kit components for administration · Drug: MMA regimen
Drug pages: Bupivacaine · Meloxicam
bupivacaine/meloxicam extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits
Also known as: ZYNRELEF
ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps.
Drug pages: Ibuprofen · Acetaminophen
PO ibuprofen 400 mg every 6 hours (q6h), alternating with PO acetaminophen 975 mg to 1 g q6h, alternating the 2 medications so that an analgesic was taken approximately every 3 hours (q3h) while the subject was awake
Also known as: ibuprofen, acetaminophen
Bupivacaine Plasma Cmax
Maximum plasma concentration of bupivacaine
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Plasma Tmax
Time to maximum concentration of bupivacaine in plasma
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Plasma t1/2
Half life of bupivacaine in plasma
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Plasma AUCinf
Area under the bupivacaine plasma concentration-time curve from Time 0 extrapolated to infinity
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Breast Milk Cmax
Maximum concentration of bupivacaine in breast milk
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Breast Milk Tmax
Time to maximum concentration of bupivacaine in breast milk
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Breast Milk AUClast
Area under the bupivacaine breast milk concentration-time curve from Time 0 to time of last quantifiable concentration
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Plasma Cmax
Maximum plasma concentrations of meloxicam
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Plasma Tmax
Time to maximum meloxicam plasma concentration in plasma
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Plasma t1/2
Half-life of meloxicam in plasma
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Plasma AUCinf
Area under the meloxicam plasma concentration-time curve from Time 0 extrapolated to infinity
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Breast Milk Cmax
Maximum concentration of meloxicam in breast milk
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Breast Milk Tmax
Time to maximum meloxicam concentration in breast milk
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Breast Milk AUClast
Area under the meloxicam breast milk concentration-time curve from Time 0 to time of last quantifiable concentration
Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
| Milestone | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Started | 14 | 11 |
| Completed | 14 | 11 |
| Not completed | 0 | 0 |
Maximum plasma concentration of bupivacaine
| ng/mL | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Bupivacaine Plasma Cmax | 238 ± 59.5 | 291 ± 69.6 |
Time to maximum concentration of bupivacaine in plasma
| hours | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Bupivacaine Plasma Tmax | 24.02 (4.08 to 48.93) | 23.70 (1.07 to 48.22) |
Half life of bupivacaine in plasma
| hours | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Bupivacaine Plasma t1/2 | 9.64 ± 2.49 | 9.95 ± 1.61 |
Area under the bupivacaine plasma concentration-time curve from Time 0 extrapolated to infinity
| h∙ng/mL | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Bupivacaine Plasma AUCinf | 13300 ± 3220 | 17500 ± 4810 |
Maximum concentration of bupivacaine in breast milk
| ng/mL | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Bupivacaine Breast Milk Cmax | 21.1 ± 12.4 | 40.1 ± 25.4 |
Time to maximum concentration of bupivacaine in breast milk
| hours | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Bupivacaine Breast Milk Tmax | 43.41 (9.45 to 106.13) | 23.50 (9.95 to 59.93) |
Area under the bupivacaine breast milk concentration-time curve from Time 0 to time of last quantifiable concentration
| h∙ng/mL | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Bupivacaine Breast Milk AUClast | 769 ± 532 | 1600 ± 1040 |
Maximum plasma concentrations of meloxicam
| ng/mL | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Meloxicam Plasma Cmax | 75.2 ± 31.7 | 114 ± 48.6 |
Time to maximum meloxicam plasma concentration in plasma
| hours | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Meloxicam Plasma Tmax | 35.57 (9.62 to 73.03) | 60.08 (8.45 to 72.80) |
Half-life of meloxicam in plasma
| hours | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Meloxicam Plasma t1/2 | 17.9 ± 5.92 | 20.2 ± 7.46 |
Area under the meloxicam plasma concentration-time curve from Time 0 extrapolated to infinity
| h∙ng/mL | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Meloxicam Plasma AUCinf | 5940 ± 2320 | 9620 ± 4540 |
Maximum concentration of meloxicam in breast milk
| ng/mL | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Meloxicam Breast Milk Cmax | 1.92 ± 1.00 | 3.06 ± 2.70 |
Time to maximum meloxicam concentration in breast milk
| hours | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Meloxicam Breast Milk Tmax | 59.23 (21.02 to 106.13) | 58.40 (11.63 to 83.45) |
Area under the meloxicam breast milk concentration-time curve from Time 0 to time of last quantifiable concentration
| h∙ng/mL | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| Meloxicam Breast Milk AUClast | 86.7 ± 59.8 | 161 ± 186 |
Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HTX-011 300 mg/9 mg | 0/14 (0%) | 1/14 (7.1%) | 12/14 (85.7%) |
| HTX-011 400 mg/12 mg + MMA | 0/11 (0%) | 1/11 (9.1%) | 8/11 (72.7%) |
| Event | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| PneumoniaInfections and infestations | 0/14 | 1/11 |
| Cardiac failure congestiveCardiac disorders | 0/14 | 1/11 |
| Gestational hypertensionPregnancy, puerperium and perinatal conditions | 1/14 | 0/11 |
| Event | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA |
|---|---|---|
| ConstipationGastrointestinal disorders | 6/14 | 2/11 |
| FlatulenceGeneral disorders | 4/14 | 3/11 |
| PruritusSkin and subcutaneous tissue disorders | 2/14 | 3/11 |
| NauseaGastrointestinal disorders | 3/14 | 0/11 |
| Anaemia postoperativeInjury, poisoning and procedural complications | 3/14 | 2/11 |
| AnaemiaBlood and lymphatic system disorders | 0/14 | 1/11 |
| HypokalaemiaMetabolism and nutrition disorders | 0/14 | 1/11 |
| HeadacheNervous system disorders | 0/14 | 1/11 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/14 | 1/11 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/14 | 1/11 |
| Age, Continuous(years) | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA | Total |
|---|---|---|---|
| Mean | 29.5 ± 5.56 | 25.9 ± 4.01 | 27.9 ± 5.17 |
| Sex: Female, Male(Participants) | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA | Total |
|---|---|---|---|
| Female | 14 | 11 | 25 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 5 |
| White | 12 | 8 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | HTX-011 300 mg/9 mg | HTX-011 400 mg/12 mg + MMA | Total |
|---|---|---|---|
| United States | 14 | 11 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in Dec 2021, 29 months.
Results were first posted in Oct 2026, 4 years 10 months after primary completion.
Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 29 months is above that.
Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bupivacaine · Meloxicam